MONTRÉAL, June 13, 2022 – ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that key findings will be presented at the 2022 Cell Therapy Transplant Canada (CTTC) Annual Meeting in Niagara Falls, Ontario. The findings were detailed in a recently published, peer-reviewed study showing that the company’s lead technology under development, ECT-001 cell therapy, improves transplant access for all patients.
Date & Time: June 17, 2022 at 16:15 EDT
Title: UM171 Expansion Of Cord Blood Improves Donor Availability And HLA Matching For All Patients, Including Minorities
Session: Oral Abstract Presentations
Presenter: Maude Dumont-Lagacé, PhD, ExCellThera, Montreal, QC, Canada
About ExCellThera Inc.
ExCellThera is a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in novel one-time curative therapies for patients with hematologic malignancies and other diseases. ExCellThera’s most advanced technology, ECT-001, a cell therapy, combines a proprietary molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its cell expansion and engineering platform, as well as supporting best-in-class clinical trials. excellthera.com
